What Is This CJC-1295 Ipamorelin Study Site?

What This Site Does and Does Not Do

CJC + Ipa Store explains published work on CJC-1295 ipamorelin. The papers cover CJC-1295 in people, rats, mice, and other animals.

This is not a clinic or shop. It has no exam room or medical staff.

No one here can diagnose, prescribe, or direct your care. The site sells no drug and fills no order.

“Store” means a stored set of papers here. It doesn't mean a place to buy medicine.

The site takes no payment and arranges no delivery. You can't order a drug here.

The pages explain 22 numbered findings. They also list 4 newer study entries.

No visits, prescriptions, or medical advice are offered. You can read the papers, but you can't receive care here.

Your health questions belong with your doctor. This site's job ends with the published studies.

What the Source Check Gives You

Each number leads to a paper in References. The sources are medical journals and ClinicalTrials.gov, a public trial list.

The list begins with a 1998 ipamorelin paper. It runs through a 2025 tesamorelin review.

Each finding says who or what was tested. A rat result stays a rat result.

Early drafts, sales papers, and user stories are left out. Missing human work is named plainly.

Human blood-time facts for ipamorelin are one such gap. You get study results, not a treatment plan.

Each number can be traced to a paper. Your reading won't be padded with sales claims.

What the Rules Say About CJC-1295 and Ipamorelin

FDA has approved neither CJC-1295 nor ipamorelin for people. Early human CJC-1295 studies ran in 2006–2009.

Those CJC-1295 studies did not lead to approval. Ipamorelin reached early work for bowel slowdown after surgery.

No main paper reports that study's outcome. Neither drug finished the large human tests usually needed for approval.

Both drugs are banned in tested sport. The ban matters to any athlete who may be tested.

CJC-1295 is in FDA's withdrawn-nomination table. The nomination's withdrawal grants no compounding permission, and FDA's safety concerns remain.

Ipamorelin acetate remains in Category 2 for 503B compounding, as FDA's safety table records. A compounded preparation has no FDA approval; an individual assessment by a licensed U.S. clinician can lead to a prescription or a refusal, with the options constrained by the state and treatment.

Is CJC-1295/ipamorelin FDA-approved? No. Early tests don't change that.

Who joined the early studies? Healthy adults aged 21–60 took part.

They had normal gland function and no active cancer. Diabetes and pregnancy also kept people out.

Those entry rules describe the study groups. They don't say who is fit to use the drugs.

For you, no FDA approval is the key rule. Early CJC-1295 work doesn't change it.

What This Site Cannot Tell You

This site helps you read published medical papers. It can't diagnose you or set your treatment.

Nothing here tells you to buy, mix, or take a drug. Bring your health concern to a trained professional.

Animal results can't tell you what will happen in your body. Human results stay tied to the people studied.

No finding gives you a personal promise. You need the limits as much as the result.

Use these pages to understand the papers. Your care still belongs with a trained professional.